R Li1,2, C Huang1,2, C Hong1,2, J Wang2, Q Li2, C Hu1,3, H Cui2, Z Dong4, H Zhu5, L Liu1,2, L Xiao1,2. 1. Big Data Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. 2. Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. 3. Department of Infectious Diseases, Guangzhou First People's Hospital, Guangzhou 510180, China. 4. Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. 5. Department of Oncology, First Affiliated Hospital of University of South China, Hengyang 421001, China.
Abstract
OBJECTIVE: To assess the impact of nonsteroidal anti-inflammatory drugs (NSAIDs) on clinical outcomes of patients receiving anti-PD-1 immunotherapy for hepatocellular carcinoma. METHODS: We conducted a retrospective study among 215 patients with primary liver cancer receiving immunotherapy between June, 2018 and October, 2020. The patients with balanced baseline characteristics were selected based on propensity matching scores, and among them 33 patients who used NSAIDs were matched at the ratio of 1∶3 with 78 patients who did not use NSAIDs. We compared the overall survival (OS), progression-free survival (PFS), and disease control rate (DCR) between the two groups. RESULTS: There was no significant difference in OS between the patients using NSAIDs (29.7%) and those who did not use NSAIDs (70.2%). Univariate and multivariate analyses did not show an a correlation of NSAIDs use with DCR (univariate analysis: OR=0.602, 95% CI: 0.299-1.213, P=0.156; multivariate analysis: OR=0.693, 95% CI: 0.330-1.458, P=0.334), PFS (univariate analysis: HR=1.230, 95% CI: 0.789-1.916, P=0.361; multivariate analysis: HR=1.151, 95% CI: 0.732-1.810, P=9.544), or OS (univariate analysis: HR=0.552, 95% CI: 0.208-1.463, P=0.232; multivariate analysis: HR=1.085, 95% CI: 0.685-1.717, P=0.729). CONCLUSION: Our results show no favorable effect of NSAIDs on the efficacy of immunotherapy in patients with advanced primary liver cancer, but this finding still needs to be verified by future prospective studies of large cohorts.
OBJECTIVE: To assess the impact of nonsteroidal anti-inflammatory drugs (NSAIDs) on clinical outcomes of patients receiving anti-PD-1 immunotherapy for hepatocellular carcinoma. METHODS: We conducted a retrospective study among 215 patients with primary liver cancer receiving immunotherapy between June, 2018 and October, 2020. The patients with balanced baseline characteristics were selected based on propensity matching scores, and among them 33 patients who used NSAIDs were matched at the ratio of 1∶3 with 78 patients who did not use NSAIDs. We compared the overall survival (OS), progression-free survival (PFS), and disease control rate (DCR) between the two groups. RESULTS: There was no significant difference in OS between the patients using NSAIDs (29.7%) and those who did not use NSAIDs (70.2%). Univariate and multivariate analyses did not show an a correlation of NSAIDs use with DCR (univariate analysis: OR=0.602, 95% CI: 0.299-1.213, P=0.156; multivariate analysis: OR=0.693, 95% CI: 0.330-1.458, P=0.334), PFS (univariate analysis: HR=1.230, 95% CI: 0.789-1.916, P=0.361; multivariate analysis: HR=1.151, 95% CI: 0.732-1.810, P=9.544), or OS (univariate analysis: HR=0.552, 95% CI: 0.208-1.463, P=0.232; multivariate analysis: HR=1.085, 95% CI: 0.685-1.717, P=0.729). CONCLUSION: Our results show no favorable effect of NSAIDs on the efficacy of immunotherapy in patients with advanced primary liver cancer, but this finding still needs to be verified by future prospective studies of large cohorts.
Entities:
Keywords:
immunotherapy; nonsteroidal anti-inflammatory drugs; primary liver cancer
Authors: Tsuyoshi Hamada; Yin Cao; Zhi Rong Qian; Yohei Masugi; Jonathan A Nowak; Juhong Yang; Mingyang Song; Kosuke Mima; Keisuke Kosumi; Li Liu; Yan Shi; Annacarolina da Silva; Mancang Gu; Wanwan Li; NaNa Keum; Xuehong Zhang; Kana Wu; Jeffrey A Meyerhardt; Edward L Giovannucci; Marios Giannakis; Scott J Rodig; Gordon J Freeman; Daniel Nevo; Molin Wang; Andrew T Chan; Charles S Fuchs; Reiko Nishihara; Shuji Ogino Journal: J Clin Oncol Date: 2017-04-13 Impact factor: 44.544
Authors: Daniel Y Wang; Jennifer L McQuade; Rajat R Rai; John J Park; Shilin Zhao; Fei Ye; Kathryn E Beckermann; Samuel M Rubinstein; Romany Johnpulle; Georgina V Long; Matteo S Carlino; Alexander M Menzies; Michael A Davies; Douglas B Johnson Journal: Oncologist Date: 2019-11-29
Authors: L Derosa; M D Hellmann; M Spaziano; D Halpenny; M Fidelle; H Rizvi; N Long; A J Plodkowski; K C Arbour; J E Chaft; J A Rouche; L Zitvogel; G Zalcman; L Albiges; B Escudier; B Routy Journal: Ann Oncol Date: 2018-06-01 Impact factor: 32.976
Authors: Vikrant V Sahasrabuddhe; Munira Z Gunja; Barry I Graubard; Britton Trabert; Lauren M Schwartz; Yikyung Park; Albert R Hollenbeck; Neal D Freedman; Katherine A McGlynn Journal: J Natl Cancer Inst Date: 2012-11-28 Impact factor: 13.506
Authors: Shang-Jui Wang; Karishma Khullar; Sinae Kim; Nikhil Yegya-Raman; Jyoti Malhotra; Roman Groisberg; Samuel H Crayton; Ann W Silk; John L Nosher; Michael A Gentile; Janice M Mehnert; Salma K Jabbour Journal: J Immunother Cancer Date: 2020-10 Impact factor: 13.751